Chemistry and Drug Metabolism, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD 21224, USA.
Clin Chem. 2011 Nov;57(11):1597-606. doi: 10.1373/clinchem.2011.169490. Epub 2011 Aug 29.
Oral fluid (OF) testing is increasingly important for drug treatment, workplace, and drugged-driving programs. There is interest in predicting plasma or whole-blood concentrations from OF concentrations; however, the relationship between these matrices is incompletely characterized because of few controlled drug-administration studies.
Ten male daily cannabis smokers received around-the-clock escalating 20-mg oral Δ(9)-tetrahydrocannabinol (THC, dronabinol) doses (40-120 mg/day) for 8 days. Plasma and OF samples were simultaneously collected before, during, and after dosing. OF THC, 11-hydroxy-THC and 11-nor-9-carboxy-THC (THCCOOH) were quantified by GC-MS at 0.5-μg/L, 0.5-μg/L, and 7.5-ng/L limits of quantification (LOQs), respectively. In plasma, the LOQs were 0.25 μg/L for THC and THCCOOH, and 0.5 μg/L for 11-hydroxy-THC.
Despite multiple oral THC administrations each day and increasing plasma THC concentrations, OF THC concentrations generally decreased over time, reflecting primarily previously self-administered smoked cannabis. The logarithms of the THC concentrations in oral fluid and plasma were not significantly correlated (r = -0.10; P = 0.065). The OF and plasma THCCOOH concentrations, albeit with 1000-fold higher concentrations in plasma, increased throughout dosing. The logarithms of OF and plasma THCCOOH concentrations were significantly correlated (r = 0.63; P < 0.001), although there was high interindividual variation. A high OF/plasma THC ratio and a high OF THC/THCCOOH ratio indicated recent cannabis smoking.
OF monitoring does not reliably detect oral dronabinol intake. The time courses of THC and THCCOOH concentrations in plasma and OF were different after repeated oral THC doses, and high interindividual variation was observed. For these reasons, OF cannabinoid concentrations cannot predict concurrent plasma concentrations.
口服液(OF)检测在药物治疗、工作场所和药物驾驶计划中变得越来越重要。人们有兴趣根据 OF 浓度预测血浆或全血浓度;然而,由于很少有受控的药物给药研究,这些基质之间的关系尚未完全确定。
10 名男性每日吸食大麻者接受了为期 8 天的 20 毫克口服 Δ(9)-四氢大麻酚(THC,dronabinol)剂量的 24 小时递增(40-120 毫克/天)。在给药前、期间和之后同时采集血浆和 OF 样本。通过气相色谱-质谱法(GC-MS)以 0.5-μg/L、0.5-μg/L 和 7.5-ng/L 的定量下限(LOQ)分别定量 OF THC、11-羟基-THC 和 11-去甲-9-羧基-THC(THCCOOH)。在血浆中,THC 和 THCCOOH 的 LOQ 为 0.25 μg/L,11-羟基-THC 的 LOQ 为 0.5 μg/L。
尽管每天多次口服给予 THC,并且血浆 THC 浓度增加,但 OF THC 浓度通常随着时间的推移而降低,主要反映了之前自我给予的吸食大麻。口服液和血浆中 THC 浓度的对数没有显著相关(r = -0.10;P = 0.065)。尽管在血浆中浓度高 1000 倍,但 OF 和血浆 THCCOOH 浓度在整个给药过程中均增加。OF 和血浆 THCCOOH 浓度的对数呈显著相关(r = 0.63;P <0.001),尽管存在个体间的高度变异性。高 OF/血浆 THC 比值和高 OF THC/THCCOOH 比值表明最近吸食了大麻。
OF 监测不能可靠地检测到口服 dronabinol 的摄入。在重复口服给予 THC 后,血浆和 OF 中 THC 和 THCCOOH 浓度的时间过程不同,并且观察到个体间的高度变异性。由于这些原因,OF 大麻素浓度不能预测同时存在的血浆浓度。